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Background
Of the millions globally infected with HIV-1, only 20-30%
will develop broadly neutralizing antibodies. To date, no
one has measured this phenomenon in a cohort of sub-
jects for which multiple aspects of B-lymphocyte dysfunc-
tion have been evaluated in parallel.
Methods
In 16 viremic seroconverters, the cross-clade neutralizing
activity of plasma was investigated using a panel of thir-
teen clade A, B, and C HIV-1 envelope (Env) pseudotyped
virions, which represented three tiers of sensitivity. The
neutralization IC50 was calculated for each plasma-Env
combination, and these data were used to determine a
breadth (how many Envs were neutralized) and potency
(the strength of neutralization) score for each seroconver-
ter. Additionally, the level of plasma antibodies that bound
to the monomeric form of a subtype B Env gp120 (HIV-1
BaL) was quantitated.
Results
A range of neutralization breadth emerged: three plasma
samples (19%) demonstrated widespread neutralizing
activity against this panel of Envs, while five subjects (31%)
exhibited a complete lack of detectable neutralization at
the lowest dilution of plasma tested (1:100). No correlation
was observed between neutralization breadth or potency
and parameters of B-lymphocyte dysfunction (PD-1,
BTLA), immune activation (Ki-67, CD95), or disease pro-
gression (CD4 T cell count, plasma viral load). The level
of total IgG in each plasma sample, however, did signifi-
cantly correlate with both neutralization breadth and
potency. Like total IgG, anti-gp120 binding antibodies also
positively correlated, but, in this case, the correlations only
trended toward significance. Anti-gp120 binding antibo-
dies did not correlate with parameters of B-lymphocyte
dysfunction, immune activation, disease progression, or
total IgG level.
Conclusion
These findings demonstrate that even in chronically HIV-
1-infected subjects in whom B-lymphocytes display multi-
ple indications of dysfunction, antibodies that mediate
cross-clade neutralization breadth (particularly anti-gp120
binding and other IgG antibody specificities) continue to
circulate in plasma.
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